DOI: https://doi.org/10.22263/2312-4156.2022.4.43
Y.H. Yupatau1, T.I. Dmitrachenko1, V.M. Semenov1, N.Y. Vasilyeva2
Liver cirrhosis: dispensary observation, the effectiveness of antiviral therapy
1Vitebsk State Order of Peoples’ Friendship Medical University, Vitebsk, Republic of Belarus
2Vitebsk Regional Clinical Infectious Diseases Hospital, Vitebsk, Republic of Belarus
Vestnik VGMU. 2022;21(4):43-51.
Abstract.
Objectives. To analyze the natural course of liver cirrhosis caused by the hepatitis C virus (HCV) and to evaluate the effectiveness of the related therapy with direct-acting antivirals (DAAs).
Material and methods. The natural course of HCV-related cirrhosis was analyzed in 132 dispensary patients, and the effectiveness of antiviral interferon-free therapy was evaluated in 85 of them.
Results. The incidence of liver cirrhosis in HCV-infected patients (9.4%) significantly exceeded that in hepatitis B virus-infected patients (2.6%). Among the dispensary patients with HCV-related cirrhosis, 46.2% were correspondingly diagnosed on registration or during the first year of dispensary observation, and 31% developed cirrhosis during the first five years of follow-up observation. The average and median terms for cirrhosis development made up 4.6 and 3.0 years, respectively. The administration of DAAs to patients with HCV-related cirrhosis resulted in a sustained virologic response in 95.3% of all cases. The absence of the effect was mainly observed in patients with liver HCV-related cirrhosis of genotype 3a (11.1%), the proportion of which in Vitebsk region reaches 29.2% in patients with chronic hepatitis C and 37.12% in patients with HCV-related cirrhosis. The rapid tests employed for the detection of antibodies to the HCV during screening were found to be more suitable for the widespread use and cost-effective.
Conclusions. The treatment of patients with HCV-related cirrhosis of all genotypes with DAAs elicited no sustained virologic response in 4.7% of all cases and in 11.1% of cases with genotype 3a. The rapid progression of liver fibrosis in patients under dispensary observation highlights the need to improve diagnostics and thus enable the efficient early detection of chronic hepatitis C and timely antiviral therapy prescription.
Keywords: chronic hepatitis C (CHC), liver cirrhosis, antibodies to the HCV, direct-acting antivirals (DAAs).
References
1. Volynkina AS, Kulichenko AN. Modern methods of molecular genetic analysis in the surveillance of the crimean-congo hemorrhagic fever. Infekcionnye bolezni: novosti, mnenija, obuchenie. 2019;8(2):64–71. doi: http://dx.doi.org/10.24411/2305-3496-2019-12009 (In Russ.)
2. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014 Nov;61(1 Suppl):S45–57. doi: http://dx.doi.org/10.1016/j.jhep.2014.07.027
3. Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016 Sep 14;22(34):7824–40. doi: http://dx.doi.org/10.3748/wjg.v22.i34.7824
4. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161–76. doi: http://dx.doi.org/10.1016/S2468-1253(16)30181-9
5. Global hepatitis report, 2017 [Electronic resource]. World Health Organization; 2017 [cited 2022 Jan 10]. 83 p. Available from: http://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-eng.pdf?sequence=1
6. Morozov VA, Lagaye S. Hepatitis C virus: Morphogenesis, infection and therapy. World J Hepatol. 2018 Feb 27;10(2):186–12. doi: http://dx.doi.org/10.4254/wjh.v10.i2.186
7. EASL recommendations on treatment of hepatitis C: Final update of the series. European Association for the Study of the Liver. J Hepatol. 2020 Nov;73(5):1170–218. doi: http://dx.doi.org/10.1016/j.jhep.2020.08.018
8. Khullar V, Firpi RJ. Hepatitis C cirrhosis: New perspectives for diagnosis and treatment. World J Hepatol. 2015 Jul 18;7(14):1843–55. doi: http://dx.doi.org/10.4254/wjh.v7.i14.1843
9. Gasich EL, Eremin VF. Geneticheskoe raznoobrazie virusa gepatita S v Respublike Belarus’. Zdravoohranenie [Jelektronnyj resurs]. 2016 [dostupno 2022 Feb 05];(10):24–28. Rezhim dostupa: https://www.zdrav.by/infektologiya-i-epidemiologiya/geneticheskoe-raznoobrazie-virusa-gepatita-s-v-respublike-belarus/
10. Lingala S, Ghany MG. Natural History of Hepatitis C. Gastroenterol Clin North Am. 2015 Dec;44(4):717–34. doi: http://dx.doi.org/10.1016/j.gtc.2015.07.003
11. Na SK, Song BC. Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C. Clin Mol Hepatol. 2019 Sep;25(3):234–44. doi: http://dx.doi.org/10.3350/cmh.2018.0108
12. Baumert TF, Berg T, Lim JK, Nelson DR. Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges. Gastroenterology. 2019 Jan;156(2):431–45. doi: http://dx.doi.org/10.1053/j.gastro.2018.10.024
13. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, Foschi FG, Lenzi M, Mazzella G, Verucchi G, Andreone P, Brillanti S. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016 Oct;65(4):727–33. doi: http://dx.doi.org/10.1016/j.jhep.2016.06.015
14. Roche B, Coilly A, Duclos-Vallee JC, Samuel D. The impact of treatment of hepatitis C with DAAs on the occurrence of HCC. Liver Int. 2018 Feb;38 Suppl 1:139–45. doi: http://dx.doi.org/10.1111/liv.13659
15. Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, Lens S, Díaz A, Vilana R, Darnell A, Varela M, Sangro B, Calleja JL, Forns X, Bruix J. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016 Oct;65(4):719–26. doi: http://dx.doi.org/10.1016/j.jhep.2016.04.008
16. Verna EC, Morelli G, Terrault NA, Lok AS, Lim JK, Di Bisceglie AM, Zeuzem S, Landis CS, Kwo P, Hassan M, Manns MP, Vainorius M, Akushevich L, Nelson DR, Fried MW, Reddy KR. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. J Hepatol. 2020 Sep;73(3):540–48. doi: http://dx.doi.org/10.1016/j.jhep.2020.03.031
17. Ob utverzhdenii klinicheskogo protokola «Diagnostika i lechenie pacientov (vzrosloe naselenie) s hronicheskimi virusnymi gepatitami B i C»: [Jelektronnyj resurs] : Postanovlenie M-va zdravoohranenija Resp. Belarus', 19 marta 2019 g., №19. Rezhim dostupa: https://pravo.by/document/?guid=12551&p0=W21934091p&p1=1 (In Russ.)
18. Ob utverzhdenii Plana meroprijatij po jeliminacii virusnogo gepatita S: Ministerstva zdravoohranenija Respubliki Belarus' [Jelektronnyj resurs] : 25 fevralja 2020 g., № 204. Rezhim dostupa: https://www.globalhep.org/sites/default/files/content/resource/files/2020-03/Belarus (In Russ.)
19. Chevaliez S, Wlassow M, Volant J, Roudot-Thoraval F, Bachelard A, Poiteau L, Trabut JB, Hézode C, Bourdel A, Dominguez S. Assessing Molecular Point-of-Care Testing and Dried Blood Spot for Hepatitis C Virus Screening in People Who Inject Drugs. Open Forum Infect Dis. 2020 May 26;7(6):ofaa196. doi: http://dx.doi.org/10.1093/ofid/ofaa196. eCollection 2020 Jun.
Information about authors:
Y.H. Yupatau – senior lecturer of the Chair of Internal Diseases Propedeutics, Vitebsk State Order of Peoples’ Friendship Medical University
E-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра. – Yury H. Yupatau,
T.I. Dmitrachenko – Doctor of Medical Sciences, professor of the Chair of Infectious Diseases with the course of the Faculty for Advanced Training & Retraining, Vitebsk State Order of Peoples’ Friendship Medical University;
V.M. Semenov – Doctor of Medical Sciences, professor, head of the Chair of Infectious Diseases with the course of the Faculty for Advanced Training & Retraining, Vitebsk State Order of Peoples’ Friendship Medical University;
N.Y. Vasilyeva – infectious disease doctor, Vitebsk Regional Clinical Infectious Diseases Hospital.
